NCT00061633 - Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI) | Biotech Hunter

Enrollment

169

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

January 31, 2004

Study Completion Date

January 31, 2004

Conditions

Infections, Gram-Positive BacterialAbscessBurnsCellulitisUlcerWound Infections

Interventions

DRUG

Telavancin

Telavancin 7.5 mg/kg/day IV (intravenously) for up to 14 days

DRUG

Vancomycin or antistaphylococcal penicillin

Vancomycin 1 Gram IV (intravenously) every 12 hrs or nafcillin 2 Grams, oxacillin 2 Grams, or (in South Africa) cloxacillin 0.5 - 1 Gram, IV (intravenously) every 6 hrs for up to 14 days.

Trial Locations (1)

91910

eStudy Site, 3450 Bonita Road, Ste 201, Chula Vista